{"id":684529,"date":"2022-09-13T08:18:51","date_gmt":"2022-09-13T12:18:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/"},"modified":"2022-09-13T08:18:51","modified_gmt":"2022-09-13T12:18:51","slug":"immutep-appoints-lag-3-pioneer-frederic-triebel-to-board","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/","title":{"rendered":"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>SYDNEY, AUSTRALIA, Sept.  13, 2022  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9HULnqI2dbnkYL4p3lTvPq5dOy6rlWCTjvp9g-WS97q18vQuGv19u2PRjaS3vjWpoMQIJdVxJl9TlMIC05Oieg==\" rel=\"nofollow noopener\" target=\"_blank\">Immutep<\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kX2yhpr4noVAKm70-9jZeK5DR-LHr5hq5N4Lx90VSZ6h0tUYtDVls1b7gjvoDle-12pFFhVcWABa01tII6JzYw==\" rel=\"nofollow noopener\" target=\"_blank\"> Limited<\/a> (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific Officer and Chief Medical Officer, Professor Fr\u00e9d\u00e9ric Triebel, M.D. Ph.D. as Executive Director. Prof. Triebel will join the Immutep Board with immediate effect.<\/p>\n<p align=\"justify\">Prof. Triebel pioneered the recently validated LAG-3 field of immuno-oncology, having discovered the LAG-3 gene, its functions and medical usefulness while working at Institut Gustave Roussy (IGR), a large cancer centre in Paris. He founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer of Immutep following the Company\u2019s acquisition of Immutep S.A in December 2014. While working at IGR as an oncologist, he was also a Professor in Immunology at Paris University and a Director of an INSERM Unit from 1991 to 1996.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Immutep <\/strong><br \/>\n        <strong>Chair<\/strong><br \/>\n        <strong>, <\/strong><br \/>\n        <strong>Russell Howard <\/strong><br \/>\n        <strong>said:<\/strong> \u201cIt is a privilege to welcome Fr\u00e9d\u00e9ric to Immutep\u2019s Board. His discovery of the LAG-3 gene led to the emergence of LAG-3 as the 3<sup>rd<\/sup> immune checkpoint, after CTLA-4 and PD-1, earning him global industry recognition and respect. His ongoing work has positioned Immutep to lead this exciting space, with the greatest number of unique LAG-3 candidates currently in clinical development. Given Immutep\u2019s growing industry profile as we commence our commercialisation journey, it is more important than ever that Fr\u00e9d\u00e9ric is directly involved in setting our strategy.\u201d<\/p>\n<p align=\"justify\">Prof. Triebel holds an M.D. and a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 153 publications and 31 patents.<\/p>\n<p align=\"justify\">\n        <strong>Prof. Triebel said:<\/strong> \u201cI am very excited about the potential of our four LAG-3 product candidates, particularly efti which has reported strong clinical results over the last couple of years. Efti stands out for many reasons including its unique mechanism of action as an APC activator, a consistently favourable safety profile, and very good efficacy results across multiple tumour types, including patients with high unmet need. These factors are opening up multiple collaboration opportunities and commercialisation pathways for efti. I look forward to working as part of the Board to realise the value of this promising product candidate.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Immutep<\/strong><br \/>\n        <br \/>Immutep is a globally active biotechnology company that is a leader in the development of LAG-3-related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.<\/p>\n<p align=\"justify\">Immutep\u2019s current lead product candidate is eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.<\/p>\n<p align=\"justify\">Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep\u2019s large pharmaceutical partners.<\/p>\n<p align=\"justify\">Further information can be found on the Company\u2019s website <u>www.immutep.com<\/u> or by contacting:<\/p>\n<p align=\"justify\">\n        <strong>Australian Investors\/Media:<\/strong><br \/>\n        <br \/>Catherine Strong, Citadel-MAGNUS<br \/>+61 (0)406 759 268; <u>cstrong@citadelmagnus.com<\/u><\/p>\n<p align=\"justify\">\n        <strong>U.S. Media:<\/strong><br \/>\n        <br \/>Tim McCarthy, LifeSci Advisors<br \/>+1 (917) 679 9282;\u00a0<u>tim@lifesciadvisors.com<\/u><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjA0MDlkMTktYTNjMC00NzdmLThlOGYtNTFiZDk0NTczYmM0LTEwMzE0MDU=\/tiny\/Immutep-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific Officer and Chief Medical Officer, Professor Fr\u00e9d\u00e9ric Triebel, M.D. Ph.D. as Executive Director. Prof. Triebel will join the Immutep Board with immediate effect. Prof. Triebel pioneered the recently validated LAG-3 field of immuno-oncology, having discovered the LAG-3 gene, its functions and medical usefulness while working at Institut Gustave Roussy (IGR), a large cancer centre in Paris. He founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-684529","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific Officer and Chief Medical Officer, Professor Fr\u00e9d\u00e9ric Triebel, M.D. Ph.D. as Executive Director. Prof. Triebel will join the Immutep Board with immediate effect. Prof. Triebel pioneered the recently validated LAG-3 field of immuno-oncology, having discovered the LAG-3 gene, its functions and medical usefulness while working at Institut Gustave Roussy (IGR), a large cancer centre in Paris. He founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer &hellip; Continue reading &quot;Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T12:18:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board\",\"datePublished\":\"2022-09-13T12:18:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/\"},\"wordCount\":565,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/\",\"name\":\"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=\",\"datePublished\":\"2022-09-13T12:18:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/","og_locale":"en_US","og_type":"article","og_title":"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board - Market Newsdesk","og_description":"SYDNEY, AUSTRALIA, Sept. 13, 2022 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the appointment of its Chief Scientific Officer and Chief Medical Officer, Professor Fr\u00e9d\u00e9ric Triebel, M.D. Ph.D. as Executive Director. Prof. Triebel will join the Immutep Board with immediate effect. Prof. Triebel pioneered the recently validated LAG-3 field of immuno-oncology, having discovered the LAG-3 gene, its functions and medical usefulness while working at Institut Gustave Roussy (IGR), a large cancer centre in Paris. He founded Immutep S.A. in 2001 to develop LAG-3 product candidates as human medicines and became Chief Medical Officer and Chief Scientific Officer &hellip; Continue reading \"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-13T12:18:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board","datePublished":"2022-09-13T12:18:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/"},"wordCount":565,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/","name":"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=","datePublished":"2022-09-13T12:18:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0NTI0NCM1MTQ5MTQ1IzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-appoints-lag-3-pioneer-frederic-triebel-to-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep Appoints LAG-3 Pioneer, Fr\u00e9d\u00e9ric Triebel to Board"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=684529"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/684529\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=684529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=684529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=684529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}